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Edited by Barry HalliwellAbstract Alpha-tocopherol transfer protein (ATTP) null mice
(ATTP/) have a systemic deﬁciency of alpha-tocopherol
(AT). The heart AT levels of ATTP/ are <10% of those in
ATTP+/+ mice. The genomic responses of heart to AT deﬁciency
were determined in 3 months old male ATTP/ mice and com-
pared with their ATTP+/+ littermate controls using Aﬀymetrix
430A 2.0 high density oligonucleotide arrays. Diﬀerential analy-
sis of 13000 genes identiﬁed repression of genes related to im-
mune system and activation of genes related to lipid metabolism
and inﬂammation with no signiﬁcant change in the expression of
classical antioxidant genes (catalase, superoxide dismutase, glu-
tathione peroxidase) in ATTP/ as compared to ATTP+/+
mice. The present data identiﬁes novel classes of AT sensitive
genes in heart tissue.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Vitamin E (VE) was ﬁrst discovered as a ‘‘reproductive fac-
tor’’ important in the maintenance of pregnancy in rats [1].
a-tocopherol (AT), a lipid-soluble antioxidant, is the most
abundant biologically active form of VE [2]. VE is absorbed
from the intestine, initially transported to systemic tissues in
chylomicrons, then following uptake of chylomicrons and theirAbbreviations: Ahsg, alpha 2-HS-glycoprotein; Alox12, arachidonate
12-lipoxygenase; AT, alpha-tocopherol; ATTP, alpha-tocopherol tra-
nsfer protein; Ccr5, chemokine (C–C motif) receptor 5; Cfd, comple-
ment factor D; Clec1b, C-type lectin domain family 1, member b;
Csnk1a1, casein kinase 1; Cxcl7, chemokine (C–X–C motif) ligand 7;
Cyp2e1, cytochrome P450, family 2, subfamily e, polypeptide 1; Fads3,
fatty acid desaturase 3; GCOS, genechip operating software; Gp1bb,
glycoprotein 1b, beta polypeptide; Gp9, glycoprotein 9; Hamp1, hep-
cidin antimicrobial peptide 1; Hmgcr, 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase; Igh-6, immunoglobulin heavy chain 6 (heavy
chain of IgM); Ighg, immunoglobulin heavy chain (gamma polypep-
tide); Igk-V8-16, immunoglobulin kappa chain variable 8 (V8)-16; Ir-
ak1, interleukin-1 receptor-associated kinase 1; Lip1, lysosomal acid
lipase 1; PKC, protein kinase C; Slpi, secretory leukocyte peptidase
inhibitor; Tnfrsf11b, tumor necrosis factor receptor superfamily, me-
mber 11b; Ubd, ubiquitin D; Ucp1, uncoupling protein 1; VE, vitamin
E
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doi:10.1016/j.febslet.2007.03.017remnants by the liver, with >90% of the absorbed tocopherols
still intact, incorporated into the secreted very low density lipo-
proteins, resulting in recirculation of VE within lipoprotein
compartments [3]. AT is preferentially incorporated into the
secreted lipoproteins due to its high aﬃnity of AT for transfer
protein (ATTP), a protein found predominantly in the liver [4].
The biological activity of AT is thus dependent upon its deliv-
ery to tissues, and decreases in the binding capacity or aﬃnity
of ATTP for AT will limit the secretion of AT into lipoproteins
and the subsequent delivery to peripheral tissues. In the
ATTP/ mice, low AT concentrations are present in plasma
(approx. 5% of ATTP+/+) and in extra-hepatic tissues, includ-
ing heart (2–20%), but liver concentrations remain approxi-
mately 40% of those of ATTP+/+ mice [5].
Atherosclerotic cardiovascular diseases, a major cause of
death in the United States, are believed to be related in part
to lipid peroxidative processes occurring in blood vessel walls.
As AT represents the major biologic lipophilic antioxidant,
many clinical trials have tested the eﬃcacy of AT alone or in
combination with other antioxidants to ameliorate cardiovas-
cular diseases, but with results that are generally negative
and at best far from clear [6,7]. Little has been reported con-
cerning heart tissue genomic responses to AT. The present
study was carried out to identify global gene expression
changes in heart tissue as a result of AT deﬁciency secondary
to deletion of the ATTP gene.2. Materials and methods
2.1. Animals and diet
The protocols for the care and use of animals were approved by the
Institutional Care and Use Committee at the University of California,
Davis. Male C57BL/6 mice with a deletion of ATTP gene (ATTP/)
and littermate wild type mice (ATTP+/+) were used from our colonies,
which originated from that described by Terasawa et al. [8]. The mice
were housed in polycarbonate cages in a room maintained at 21–23 C
and 60–70% humidity on a 12 h light/dark schedule and with ad libitum
access to water and food. The oﬀsprings were genotyped as previously
described [8]. After weaning, the oﬀsprings were fed diets containing 35
IU dl-tocopheryl acetate per kg diet (USB Corporation, Cleveland,
OH). At 12–14 weeks the animals were sacriﬁced by i.p. injection of
beuthanasia (120 mg/kg body weight), blood was obtained by cardiac
puncture and tissue samples were obtained and stored at 80 C until
further processing.
2.2. RNA extraction, gene chip analysis & statistics
Total RNA from heart tissue was extracted and processed for Gene-
Chip analysis. RNA from heart tissues were extracted with Trizol re-
agent and puriﬁed and quantiﬁed according to the manufacturer’s
(Invitrogen) protocol. An equal aliquot (5 lg) of total RNA extractblished by Elsevier B.V. All rights reserved.
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of mice (n = 4) was combined. An aliquot (20 lg) of pooled RNA solu-
tion was used for preparation of biotin-labeled RNA for hybridization
using Aﬀymetrix Mouse 430A 2.0 arrays containing oligonucleotide
probes for 22690 genes (Santa Clara, CA, USA). The scanned
images of hybridization signals were analyzed with the Aﬀymetrix
GeneChip Operating Software (GCOS 1.4) and Data Mining Tool
software. The absolute mRNA expression (present or absent) and dif-
ferential (ATTP+/+ vs ATTP/) mRNA expression data were ob-
tained from the pivot data. GeneChips contain 11 pairs of probes to
obtain speciﬁc and non-speciﬁc binding. Net binding intensities for
each mRNA were computed by GCOS 1.4, each pair of probes result-
ing in a total of 11 intensities for each mRNA. Mean, standard devia-
tion and p values are calculated from these data. When the P value for
detection signal was <0.049 (range of P value 0.0002–0.049), the
expression of the mRNA was classiﬁed as present (P). All mRNAs
with the P value for detection >0.05 were considered absent (A). Genes
whose expression changed by P 2-fold were considered for further
analyses. We also performed Gene Ontology (GO) analysis to assess
the content of diﬀerentially expressed genes for characterizing the bio-
logical properties and generated heat-map by dChip software [9].3. Results
Though the direct action of AT on heart tissue is not clear,
early studies suggested a relationship of nutritional VE deﬁ-
ciency to cardiomyopathy [10,11] and postulated it to be the
consequences of oxidative stress [12]. In the present study,
we analyzed the global gene expression proﬁle of heart tissue
of ATTP/ mice which have systemic deﬁciency of AT. The
microarray analysis by Aﬀymetrix gene chips detected
13192 genes out of which 65 genes were aﬀected in heart tis-
sue of ATTP/ mice as compared to that of ATTP+/+ mice.
Of these 65 genes, 34 were upregulated (30 with known func-
tions; 4 unknown functions) and 31 were downregulated (28
with known functions; 3 unknown functions). The diﬀeren-
tially expressed genes were classiﬁed by GO ontology
(www.geneontology.org) using dChip software. Genes related
to immune responses (19%) were seen to be largely aﬀected
by AT deﬁciency and genes related to the regulation of cellular
physiological processes and protein modiﬁcation (10% and 8%,Fig. 1. Functional classiﬁcation of diﬀerentially expressed heart genes in A
expressed genes was obtained with GCOS 1.4 software. The list was then ed
edited list of genes was subjected to GO ontology software and classiﬁed accor
several functional groups as per its biological function.respectively) were also seen to be aﬀected (Fig. 1). The heat-
map of the diﬀerentially expressed genes with known functions
generated by dChip software is reported in Fig. 2. Downregu-
lated and upregulated genes listed according to molecular
function are reported in Tables 1 and 2, respectively.
Of note, a cluster of genes related to immune functions (Igk-
V8-16, Igj, Ighg, Igh-6, Ubd, Slpi, Cfd) were downregulated
(Table 1) whereas genes related to lipid metabolism (Hmgcr,
Lip1, Alox12, Fads3, Ucp1) and inﬂammatory response (Gp9,
Tnfrsf11b, Gp1bb, Hamp1, Clec1b, Ccr5, Cxcl7, Irak1) were
upregulated (Table 2).4. Discussion
The present study was carried out to analyze the global gene
expression proﬁling of heart tissue of ATTP/ mice deﬁcient
in AT. We have previously reported low heart AT levels
(1.97 ± 0.52 nmol/g wet weight tissue) in ATTP/ mice as
compared to their respective ATTP+/+ controls (16.02 ±
4.46 nmol/g wet weight tissue) fed a basal diet [13], heart AT
levels in ATTP/mice thus being approximately 10% of levels
of their ATTP+/+ littermates. AT levels from human myocar-
dial biopsies have been reported to be 61 ± 4 nmol/g wet weight
tissue [14], which is approximately four times higher than the
myocardial levels found in the ATTP+/+ mice [13]. The plasma
AT levels of ATTP+/+ mice, ATTP/ mice and humans are
reportedly  4.5 lmol/l, 0.5 lmol/l [13] and 17 lmol/l [15],
respectively, and suggest that myocardial AT levels are related
to plasma AT levels.
ATTP gene expression was not detected in heart tissues of
ATTP+/+ mice, conﬁrming our earlier reported data on
heart ATTP mRNA by RT-PCR analysis in ATTP+/+ and
ATTP/ mice [15] and in human heart tissue by Arita et al.
[16]. Hence the drop in heart AT levels in ATTP/ mice is
likely attributed to lower plasma AT concentrations [5].
Though AT deﬁciency is suggested to cause oxidant-antioxi-
dant imbalance leading to oxidative stress [12], in the presentTTP/ mice as compared to ATTP+/+ mice. The list of diﬀerentially
ited to select genes of known function that change by P 2-fold. The
ding to biological functions. Note that same genes might be included in
Fig. 2. Heat-map of identiﬁed diﬀerentially expressed heart genes in ATTP/ mice as compared to ATTP+/+ mice generated by dChip software. The
list of diﬀerentially expressed, AT-sensitive genes was obtained with GCOS software. The list was further edited to delete genes of unknown function
and to focus on genes that change by P2-fold. The edited list of AT-sensitive genes was subjected to ‘‘hierarchial cluster analysis’’ with dChip
software. The analysis identiﬁed two major clusters. The ‘‘two-colour’’ heat map shows downregulated (blue) and upregulated (pink) genes.
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oxidant genes such as catalase, superoxide dismutase or gluta-
thione peroxidase in heart tissues of ATTP/ mice as
compared to their ATTP+/+ littermates. We have recently re-
ported similar observations in lung tissues of ATTP+/+ mice
fed an AT deﬁcient diet [17] and in lungs of ATTP/mice [18].
Several antioxidant clinical trails testing the eﬃcacy of AT
on cardiovascular and related diseases were inconclusive
[6,7]. This and other considerations have prompted researchers
to explore the modulation of biological systems by AT beyond
its ‘‘non-antioxidant’’ properties. In 1988, Mahoney and Azzi,
for the ﬁrst time, reported the inhibitory eﬀect of AT on brain
protein kinase C (PKC) activity in vitro [19]. AT-induced PKC
inhibition was also reported to inhibit smooth muscle cell pro-
liferation and platelet adhesion, aggregation and release reac-
tions, both believed to be independent of AT antioxidant
properties [20–23]. AT also inhibited native and oxidized low
density lipoprotein (LDL)-induced PKC activity and prolifer-
ation of vascular smooth muscle cells, thus aﬀecting processes
related to atherogenesis [24]. Of note, AT itself has not been
noted to be deﬁcient in human atherosclerotic plaques in spite
of the presence of co-existing oxidized lipids [25]. One possibleexplanation is that the oxidation of lipoproteins by two elec-
tron reactions, such as by hypochlorite and peroxynitrite, is
not known to be quenched by AT [26,27].
Meydani and Tengerdy have reported that AT is essential for
maintaining optimal immune system functions [28] and that AT
deﬁciency dysregulates immune responses and increase suscep-
tibilities to various infections [29,30]. Supplementation of AT
to old mice infected by inﬂuenza virus was reported to improve
immune response by increasing T helper 1 (Th1) cytokines [31]
and by decreasing the age-associated decline in CD(+) T cells
signalling [32]. In the present study, a cluster of genes related
to immune function was seen to be downregulated in heart
tissues of ATTP/ mice (Table 1). The immunoglobulin
related genes, such as immunoglobulin kappa chain variable
8 (V8)-16 (Igk-V8-16), immunoglobulin joining chain (IgJ),
immunoglobulin heavy chain (gamma polypeptide) (Ighg)
and immunoglobulin heavy chain 6 (heavy chain of IgM)
(Igh-6) were downregulated by 19.7, 14.9, 13 and 7 fold,
respectively (Table 1). We had previously reported similar
observations in lung genomic proﬁles of ATTP/ mice [18].
AT deﬁciency was also reported to intensify viral infections
and myocardial injury in mice fed AT-deﬁcient diets [33].
Table 1
Downregulated genes in heart tissue of ATTP/ mice as compared to ATTP+/+ mice
Probe set ID Gene title Gene symbol Fold change
Immune response
1452417_x_at Immunoglobulin kappa chain variable 8 (V8)16 Igk-V8-16 19.7
1424305_at Immunoglobulin joining chain Igj 14.9
1424631_a_at Immunoglobulin heavy chain (gamma polypeptide) Ighg 13.0
1452463_x_at Immunoglobulin kappa chain complex – 12.1
1427329_a_at Immunoglobulin heavy chain 6 (heavy chain of IgM) Igh-6 7.0
1419762_at Ibiquitin D Ubd 9.2
1448377_at Secretory leukocyte peptidase inhibitor Slpi 2.1
1417867_at Complement factor D (adipsin) Cfd 2.6
1421564_at Serine (or cysteine) peptidase inhibitor, clade A, member 3C Serpina3c 2.3
Signal transduction
1451497_at Casein kinase 1, alpha 1 Csnk1a1 26.0
1432453_a_at Membrane-spanning 4-domains, subfamily A, member 10 Ms4a10 10.6
1450863_a_at Doublecortin and calcium/calmodulin-dependent protein kinase-like 1 Dcamkl1 4.0
1426090_a_at Fer (fms/fps related) protein kinase, testis speciﬁc 2 Fert2 3.7
1423226_at Membrane-spanning 4-domains, subfamily A, member 1 Ms4a1 2.6
Extracellular matrix protein
1450134_at Lsyl oxidase-like 4 Loxl4 5.3
Lipid metabolism
1417871_at Hydroxysteroid (17-beta) dehydrogenase 7 Hsd17b7 4.6
1420584_at Phospholipase A2, group IIC Pla2g2c 3.5
Transcription factors
1450695_at Aryl-hydrocarbon receptor Ahr 4.0
1451059_at Zinc ﬁnger protein 474 Zfp474 2.8
1421550_a_at Tripartite motif protein 34 Trim34 2.1
Xenobiotic metabolism
1415994_at Cytochrome P450, family 2, subfamily e, polypeptide 1 Cyp2e1 2.1
Ion transport
1438809_at ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 Atp5c1 2.0
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the activation of the alternate pathway innate immunity [34],
was downregulated by 2.6 fold. Cfd, secreted from cells of
nervous tissue and adipocytes, has been implicated to regulate
fat metabolism [35]. Secretory leukocyte peptidase inhibitor
(Slpi) which protects against microbial infection and subse-
quent inﬂammation [36], was also downregulated by 2.1 fold.
Ubiquitin D (Ubd; or FAT10) was downregulated by 9.2
fold. Of note, the lymphocytes of Ubd deﬁcient mice were seen
to be more prone to spontaneous apoptotic death and demon-
strated high sensitivity to endotoxin challenge [37]. Casein ki-
nase 1 (Csnk1a1), a serine/threonine protein kinase which
phosphorylates a variety of substrates [38], was seen to be
downregulated by 26 fold. This is particularly interesting as
casein kinase 1 is known as a positive regulator of Wnt path-
way [39], and the interruption of this pathway in heart might
lead to impaired tissue remodeling [40].
The upregulation of mRNA encoding 3-hydroxy-3-methyl-
glutaryl-Coenzyme A reductase (Hmgcr), the key enzyme for
cholesterol biosynthesis, lysosomal acid lipase 1 (Lip1), fatty
acid desaturase 3 (Fads3) [41,42] by 8.0, 2.6 and 2.5
fold, respectively, suggests dysregulated lipid metabolism in
hearts of ATTP/ mice. The upregulation of lipid homeosta-
sis related genes were also observed in lungs of ATTP/
mice [18]. Uncoupling protein 1 (Ucp-1), a mediator of pro-
ton leakage in mitochondria and believed to be involved inthermogenesis and energy expenditure [43], and suggested
to play a role in the transport of fatty acids across mito-
chondrial membrane [44], was upregulated by 3.2 fold (Table
2).
Genes encoding glycoprotein 9 (Gp9) and glycoprotein Ib,
beta polypeptide (Gp1bb), factors relating to platelet activation
and aggregation [45], were upregulated by 8.6 and 2.8 fold,
respectively (AT supplementation was reported to inhibit
platelet aggregation [21]). Tumor necrosis factor receptor
superfamily, member 11b (Tnfrsf11b; osteoprotegerin), which
was upregulated by 4.6 fold, was recently reported to be ele-
vated in patients with atherosclerotic cardiovascular disease
[46]. The above mentioned genes, as well as the upregulation
of other genes related to inﬂammatory processes such as those
encoding arachidonate 12-lipoxygenase (Alox12) [47], chemo-
kine (C–C motif) receptor 5 (Ccr5) [48], chemokine (C–X–C
motif) ligand 7 (Ccl7) [49] and interleukin-1 receptor-associ-
ated kinase 1 (Irak-1) [50], suggest increased inﬂammatory re-
sponses in ATTP/ cardiac tissues as a result of AT
deﬁciency, as observed in our earlier reports in ATTP/ lung
and liver tissues [51]. Expression of alpha 2-HS-glycoprotein
(Ahsg), which shows negative acute-phase reactant properties,
was upregulated by 2.1 fold and has been identiﬁed in the
mineralized matrix of calciﬁed plaques of atherosclerotic hu-
man aortas [52]. It is interesting to note that cytochrome
P450-2E1 (Cyp2e1), which has a capability of initiating lipid
Table 2
Upregulated genes in heart tissue of ATTP/ mice as compared to ATTP+/+ mice
Probe set ID Gene name Gene symbol Fold change
Lipid metabolism
1427229_at 3-Hydroxy-3-methylglutaryl-Coenzyme A reductase Hmgcr 8.0
1423140_at Lysosomal acid lipase 1 Lip1 2.6
1422699_at Arachidonate 12-lipoxygenase Alox12 2.5
1449219_at Fatty acid desaturase 3 Fads3 2.5
1418197_at Uncoupling protein 1 (mitochondrial, proton carrier) Ucp1 3.2
Inﬂammatory response
1919720_at Glycoprotein 9 Gp9 8.6
1449033_at Tumor necrosis factor receptor superfamily, member 11b Tnfrsf11b 4.6
1422977_at Glycoprotein 1b, beta polypeptide Gp1bb 2.8
1419196_at Hepcidin antimicrobial peptide 1 Hamp1 2.5
1421182_at C-type lectin domain family 1, member b Clec1b 2.3
1424727_at Chemikine (C–C motif) receptor 5 Ccr5 2.1
1418480_at Chemokine (C–X–C motif) ligand 7 Cxcl7 2.1
1455093_a_at Alpha-2-HS-glycoprotein Ahsg 2.1
1460649_at Interleukin-1 receptor-associated kinase 1 Irak1 2.0
1418669_at Perlecan (heparin sulfate proteoglycan 2) Hspg2 2.0
Cytoskeletal function
1456069_at Dystrobrevin alpha Dtna 4.6
1428781_at Dermokine Dmkn 2.6
Binding protein
1423231_at Neurogranin Nrgn 3.5
Transporter
1455898_x_at Solute carrier family 2 (facilitated glucose transporter), member 3 Slc2a3 3.2
Transcription factors
1422565_s_at Nuclear factor I/C Nﬁc 2.3
1419874_x_at Zinc ﬁnger and BTB domain containing 16 Zbtb16 2.3
1416348_at Multiple endocrine neoplasia 1 Men1 2.1
1449534_at Synaptonemal complex protein 3 Sycp3 2.1
1423603_at Zinc ﬁnger protein, multitype 1 Zfpm1 2.1
1424667_a_at Cut-like 1 (Drosophila) Cutl1 2.0
1426242_at Polymerase (RNA) II (DNA directed) polypeptide A Polr2a 2.0
Other functions
1416032_at Transmembrane protein 109 Tmem109 2.6
1421664_a_at Phosphoserine/threonine/tyrosine interaction protein Styx 2.3
1452485_at Phosphatase, orphan 1 Phospho1 2.0
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downregulated by 2.1 fold.
Patients with 744 del A mutation on ATTP gene were
reported to show cardiomyopathy as evidenced by echocardi-
ography, but this was not observed in all patients with this dis-
order [54]. In the present studies we have not investigated for
evidences of cardiomyopathy in ATTP/ mice. Further stud-
ies are warranted in these regard.
In summary, we report a preliminary characterization of the
genomic proﬁle in heart tissues of AT deﬁcient mice occurring
as a result of ATTP gene deletion. The data suggest dysregula-
tion in lipid metabolism and immune-related functions in
ATTP/ mice. The implications of the current observations
to human cardiomyopathies associated with activation of
inﬂammatory processes and oxidative stress remain to be char-
acterized. The present microarray data failed to detect modiﬁ-
cations of classical antioxidant genes (catalase, superoxide
dismutases or glutathione peroxidases), further suggesting that
non-antioxidant properties of AT are likely responsible for the
presently archived modulations in cardiac gene expression
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